PRESS-RELEASE ·Filed May 8, 2026
Press release · Announcement
Actionable Insight • Neutral
Monitor for any clinical updates or partnership discussions that may arise from the conference. No immediate trading catalyst.
Final — all horizons settled through T+60d
ALLR ▼ -15.48% at T+60d
NEUTRAL call -15.48% · α vs SPY -20.32% · entry $1.55 → $1.31
T+1d
+8.39%
call +8.39% · α +8.16%
$1.68
settled 6mo ago
T+5d
-2.58%
call -2.58% · α -4.04%
$1.51
settled 6mo ago
T+20d
+3.87%
call +3.87% · α +3.85%
$1.61
settled 5mo ago
T+60d
-15.48%
call -15.48% · α -20.32%
$1.31
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Allarity Therapeutics CEO Thomas Jensen will present at Precision Medicine Forum Europe 2026 on May 11, discussing stenoparib's dual PARP/WNT inhibition and the companion diagnostic DRP. The presentation is a routine corporate update with no new clinical data or financial announcements.
Key Facts
- CEO to present at Precision Medicine Forum Europe on May 11, 2026 in Stockholm.
- Presentation covers stenoparib (dual PARP/WNT inhibitor) and Stenoparib DRP biomarker.
- Company has ongoing Phase 2 trials in ovarian cancer and SCLC.
- No new clinical data or financial guidance disclosed.
Financial Impact
No financial impact from this event.
Risk Factors
- No new data or milestones announced.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291069 |
20 reports for ALLR
57% Hit rate @ T+20 Went positive at some point 6 of 7 best @ T+60▲ +38.71%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $1.04 | awaiting T+20 | — | $0.9001 (−13.45%) |
Sep 29, 2026 28d ago | 8-K | $0.9651 | awaiting T+20 | — | $0.9001 (−6.74%) |
Sep 28, 2026 29d ago | Press Release | $0.9684 $0.9151 | ▼ −5.50% | ▼ −5.47% | $0.9001 (−7.05%) |
Sep 16, 2026 5w ago | 8-K | $1.16 $0.8699 | ▼ −24.68% | ▼ −27.86% | $0.9001 (−22.07%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $0.8601 | ▼ −26.49% | ▼ −28.75% | $0.9001 (−23.07%) |
Sep 11, 2026 6w ago | Press Release | $1.22 $0.9900 | ▼ −18.85% | ▼ −20.72% | $0.9001 (−26.22%) |
Aug 14, 2026 10w ago | Press Release | $1.37 $1.17 | ▼ −14.60% | ▼ −12.61% | $0.9001 (−34.30%) |
Jul 1, 2026 16w ago | 8-K | $1.33 $1.16 | ▼ −12.78% | ▼ −10.60% | $0.9001 (−32.32%) |
Jun 22, 2026 18w ago | 8-K | $1.36 $1.19 | ▼ −12.50% | ▼ −12.35% | $0.9001 (−33.82%) |
Jun 18, 2026 18w ago | Press Release | $1.43 $1.17 | ▼ −18.18% | ▼ −18.71% | $0.9001 (−37.06%) |
Showing 10 of 20
US Market Status
Market Open — Closes in 3h 55m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers